Reference-Scaled Average Bioequivalence [RSABE / ABEL]

posted by Brus – Spain, 2023-06-06 14:18 (348 d 02:37 ago) – Posting: # 23578
Views: 1,477

Dear all,

I have reviewed the RSABE design possibilities according new draft FDA guideline Bioequivalence Studies With Pharmacokinetic End­points for Drugs Submitted Under an ANDA and in accordance with FDA Draft Guidance on Progesterone; regarding RSABE. And it is set out as follow:

- Full replicate: 4-ways, 2-sequences: TRTR/RTRT
- Partial replicate: 3-ways, 3-sequences: TRR / RTR / RRT

But nothing is said about the option full-replicate 3-ways, 2-sequences: TRT / RTR, which does seem to be included in the guideline Statistical Approaches to Establishing Bioequivalence. Does this mean that this design can no longer be used?

Thank you so much

Best regards,

Edit: Guidances linked. [Helmut]

Complete thread:

UA Flag
 Admin contact
23,029 posts in 4,834 threads, 1,644 registered users;
41 visitors (0 registered, 41 guests [including 7 identified bots]).
Forum time: 16:55 CEST (Europe/Vienna)

We must be careful not to confuse data with the abstractions
we use to analyze them.    William James

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz